Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial (Q48647481)

13 February 2018

title

Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial (English)

1 reference

13 February 2018

main subject

phase II clinical trial

0 references

author

Mohsen Khademi

5

1 reference

13 February 2018

Jan Fagius

Jan Fagius

7

0 references

Anne-Marie Landtblom

Anne-Marie Landtblom

9

0 references

Anders Svenningsson

Anders Svenningsson

4

0 references

Frederik Barkhof

12

Frederik Barkhof

1 reference

13 February 2018

1

Joep Killestein

1 reference

13 February 2018

author name string

Tomas Olsson

2

1 reference

13 February 2018

Erik Wallström

3

1 reference

13 February 2018

Lance D Blumhardt

6

1 reference

13 February 2018

Jan Hillert

8

1 reference

13 February 2018

Charlotte Edenius

10

1 reference

13 February 2018

Leopold Arfors

11

1 reference

13 February 2018

Chris H Polman

13

1 reference

13 February 2018

publication date

1 April 2002

1 reference

13 February 2018

published in

Annals of Neurology

1 reference

13 February 2018

volume

51

1 reference

13 February 2018

issue

4

1 reference

13 February 2018

page(s)

467-474

1 reference

13 February 2018

Immunopathogenesis of multiple sclerosis: the role of T cells

cites work

1 reference

Major T-cell responses in multiple sclerosis.

21 January 2018

1 reference

Critical Influences of the Cytokine Orchestration on the Outcome of Myelin Antigen‐Specific T‐Cell Autoimmunity in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis

21 January 2018

1 reference

Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma

21 January 2018

1 reference

Immunological aspects of demyelinating diseases

21 January 2018

1 reference

Preferential T-cell receptor beta-chain variable gene use in myelin basic protein-reactive T-cell clones from patients with multiple sclerosis

21 January 2018

1 reference

Expansion of a recurrent V beta 5.3+ T-cell population in newly diagnosed and untreated HLA-DR2 multiple sclerosis patients

21 January 2018

1 reference

Selection for T-cell receptor Vβ–Dβ–Jβ gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis

21 January 2018

1 reference

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis.

21 January 2018

1 reference

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

21 January 2018

1 reference

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial

21 January 2018

1 reference

Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans

21 January 2018

1 reference

MHC-Restricted Depletion of Human Myelin Basic Protein-Reactive T Cells by T Cell Vaccination

21 January 2018

1 reference

T cell receptor V genes in multiple sclerosis: increased use of TCRAV8 and TCRBV5 in MBP-specific clones

21 January 2018

1 reference

Detection of skewed T-cell receptor V-beta gene usage in the peripheral blood of patients with multiple sclerosis.

21 January 2018

1 reference

Lack of restriction of T cell receptor beta variable gene usage in cerebrospinal fluid lymphocytes in acute optic neuritis

21 January 2018

1 reference

Detection of intracellular expression and secretion of interferon-γ at the single-cell level after activation of human T cells with tetanus toxoidin vitro

21 January 2018

1 reference

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial

21 January 2018

1 reference

Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis

21 January 2018

1 reference

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis

21 January 2018

1 reference

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand

21 January 2018

1 reference

Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis

21 January 2018

1 reference

Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ANA.10146

1 reference

13 February 2018

1 reference

13 February 2018